Why the study?
Do coumarins started before coronary angioplasty with a target INR of 2.1 to 4.8 reduce procedural and late events in patients undergoing coronary angioplasty?
Do coumarins started before coronary angioplasty with a target INR of 2.1 to 4.8 reduce procedural and late events in patients undergoing coronary angioplasty?
Coumarin therapy with a target INR of 2.1 to 4.8 before and after coronary angioplasty may reduce procedural and late events without increasing bleeding risk.
Answers are grounded in this paper and cite their sources.
May support optimized anticoagulation to reduce late events after angioplasty; leaves open need for randomized confirmation.
Coumarins started before coronary angioplasty with a target INR of 2.1 to 4.8 led to the lowest procedural event rate, without an increase in bleeding episodes. During follow-up, optimal anticoagulation was associated with a decrease in the incidence of late events by 67% and a significant improvement in 6-month angiographic outcome.
No takes yet. Share an insight, caveat, or question.
Berg et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: